替吉奥联合多西他赛对转移性乳腺癌患者血清VEGF、CA72-4 水平及生活质量的影响

Objective: To study the effects of tegafur combined with docetaxel on the serum levels of serum VEGF,CA72-4 and life qualities in patients with metastatic breast cancer (MBC). Methods: 90 patients with MBC in our hospital from April 2015 to December 2016 were enrolled in this study, and they were divided into the control group and the treatment group according to random number table method, with 45 cases in each group. The control group were treated with xeloda combined with docetaxel, the treatment group were treated with tegafur combined with docetaxel. The patients of two groups were given continuous treatment for 2 courses. The clinical efficacy and life qualities of the two groups after treatment were compared. The serum levels of VEGF-A, VEGF-C, CA72-4 in the two groups before and after treatment were compared, and the incidence of adverse reactions of the two groups during treatment were compared. Results: The total effective rate of the treatment group was significantly higher than the control group (P<0.05). There were no significantly differences in the serum levels of VEGF-A, VEGF-C and CA72-4 in the two groups before treatment (P>0.05). The serum levels of VEGF-A, VEGF-C and CA72-4 in the two groups after treatment were significantly lower than before treatment, and the treatment group were significantly lower than the control group (P<0.05). The improvement rate of life qualities in the treatment group after treatment was significantly higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The clinical efficacy of tegafur combined with docetaxel in the treatment of MBC is obvious, and it can significantly improve life qualities of patients, reduce the serum levels of VEGF-A, VEGF-C and CA72-4, which is worthy clinical application. [ABSTRACT FROM AUTHOR]